IMPORTANCE OF MARKERS OF THE PROLIFERATION AND APOPTOSIS FOR OVARIAN BODERLINE TUMOURS

Abstract

For today, one of actual problems in gynecologic pathology are borderline tumours of the ovary to which frame of a case rate the high specific gravity is compounded by women of reproductive age. Thereupon often there is a question about safety treatment methods, that dictates necessity of an assessment of risk of development of recurrence of disease. In present article attempt to define prognostic importance of markers of proliferative activity (ki67, cyclin D1, p21), and pro-and antiapoptotic markers (p53, bax, bcl-2, survivin) for definition potentially an aggressive behavior of ovarian borderline tumour.

Keywords

ki67 / p21 / p53 / bax / bcl-2 / ovarian borderline tumour / ki67 / cyclin D1 / p21 / p53 / bax / bcl-2 / survivin

References

[1] Вольпина О.М. Ингибитор апоптоза сурвивин при переходно-клеточном раке мочевого пузыря / О.М. Вольпина // Архив патологии. – 2011. – №2. – С. 8-10.

[2] Assignment of the gene(s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10 / Schonk D.M. Schonk. [et al.] // Hum. Genet. – 1989. – Vol. 83, № (3). – P. 297-299.

[3] Bax protein expression and clinical outcome in epithelial ovarian cancer / Y.T. Tai [et al.] // J. Clin. Oncol. – 1998. – Vol. 16. – P. 2583-2590.

[4] Cyclin D1 expression is regulated by the retinoblastoma protein / H. Müller H. [et al.] // Proc. Natl. Acad. Sci. USA. – 1994. – Vol. 91. – P. 2945-2949.

[5] Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: a retrospective study. / N.O. Barisik [et al.] // Diagn. Pathol. – 2010. – Vol. 5. – P. 19.

[6] Expression of Pro-Apoptotic (p53, p21, bax, bak and fas) and Anti-Apoptotic (bcl-2 and bcl-x) Proteins in Serous Versus Mucinous Borderline Ovarian Tumours / R. Fauvet R [et al.] // J. Surg. Oncol. – 2005. – Vol. 92. – P. 337-343.

[7] Immunohistochemical localization of survivin in serous tumors of the ovary / B. Tringler B. [et al.] // Appl. Immunohistochem. Mol. Morphol. – 2004. – Vol. 12. – P. 40-43.

[8] Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors / V. Ouellet V. [et al.] // BMC Cancer. – 2008. – Vol. 8. – P. 346-353.

[9] Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors / H. Ozer, H. [et al.] // Diagn. Pathol. – 2012. – Vol. 7, №(1). – P. 124.

[10] Shin I. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges / I. Shin, R. Kurman // Clin. Cancer Res. – 2005 – Vol. 11, № (20). – P. 7273-7279.

[11] Sylvia M.T. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables / M.T. Sylvia, S. Kumar, P. Dasari // Indian J. Pathol. Microbiol. – 2012. – Vol. 55. – P. 33-37.

[12] The concurrent expression of p27 (kip1) and cyclin D1 in epithelial ovarian tumors / L. Sui L. [et al.] // Gynecol. Oncol. – 1999. – Vol. 73. – P. 202-209.

[13] Weinberg R.A. Tumor suppressor genes. / R.A. Weinberg // Science – 1991. Vol. 254. – P. 1138- 1146.

RIGHTS & PERMISSIONS

Vinogradov I.I., Zavalishina L.E., Andreeva Y.Y., Akhidova E.V., Volpina O.M., Volkova T.D., Koroev D.O.